Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|The Breast|2023Cited by 25
CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancerAnna-Maria Lazaratos, Matthew Dankner, Kevin Petrecca et al.|The Lancet Oncology|2024Cited by 3
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophilsJohn Heath, Josie Ursini‐Siegel, Caitlyn Mourcos et al.|Science Advances|2025Cited by 3
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Anna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|Journal of Clinical Oncology|2023Cited by 0